Travere Therapeutics (TVTX) Research & Development (2013 - 2026)
Travere Therapeutics' (TVTX) quarterly Research & Development came in at $57.1 million in Q1 2026, up 21.76% YoY from $46.9 million in Q1 2025, and down 1.34% on a QoQ basis from $57.9 million in Q4 2025.
Travere Therapeutics (TVTX) Research & Development (2013 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 14 years of Research & Development data on file, last reported at $57.1 million in Q1 2026.
- Quarterly Research & Development rose 21.76% year-over-year to $57.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $216.2 million (up 0.58% YoY) and the FY2025 annual result came in at $206.0 million, down 5.28% from the prior year.
- Research & Development fell to $57.1 million in Q1 2026, from $57.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $66.5 million in Q2 2023 to a low of $46.9 million in Q1 2025.
- A 5-year average of $56.3 million and a median of $57.1 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development decreased 18.29% — and 2026, when it increased 21.76%.
- Tracing TVTX's Research & Development over 5 years: stood at $58.1 million in 2022, then climbed by 2.86% to $59.7 million in 2023, then gained by 3.88% to $62.1 million in 2024, then retreated by 6.76% to $57.9 million in 2025, then declined by 1.34% to $57.1 million in 2026.
- The last three Research & Development figures came in at $57.1 million (Q1 2026), $57.9 million (Q4 2025), and $51.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 60.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.28 Mn |
| Mar 31, 2026 | 57.09 Mn |
| Dec 31, 2025 | 57.87 Mn |
| Sep 30, 2025 | 51.89 Mn |
| Jun 30, 2025 | 49.36 Mn |
| Mar 31, 2025 | 46.89 Mn |
| Dec 31, 2024 | 62.07 Mn |
| Sep 30, 2024 | 51.68 Mn |
| Jun 30, 2024 | 54.33 Mn |
| Mar 31, 2024 | 49.42 Mn |
| Dec 31, 2023 | 59.75 Mn |
| Sep 30, 2023 | 60.59 Mn |
| Jun 30, 2023 | 66.49 Mn |
| Mar 31, 2023 | 58.16 Mn |
| Dec 31, 2022 | 58.09 Mn |
| Sep 30, 2022 | 57.15 Mn |
| Jun 30, 2022 | 59.68 Mn |
| Mar 31, 2022 | 56.61 Mn |
| Dec 31, 2021 | 53.00 Mn |
| Sep 30, 2021 | 48.41 Mn |